Dr. Rosenwald is the Chairman and Chief Executive of the Paramount BioCapital group of companies. The Paramount BioCapital group of companies specializes in asset management, investment banking, venture capital and direct investing within the biotechnology and life-sciences industry. Paramount BioCapital Asset Management, Inc. manages investor assets through domestic and offshore hedge funds, as well as private equity funds. Paramount BioCapital Inc., a NASD member broker dealer, specializes in conducting private placement offerings for public and private development stage biotechnology companies and has raised approximately $950,000,000 since inception. Paramount BioCapital Investments, LLC is a venture capital organization that takes a controlling interest in public and private companies, including start-ups and distressed turn-around companies. Dr. Rosenwald has been a Wall Street biotechnology entrepreneur for over 17 years. The senior staff at the Paramount Group has backgrounds in both the medical and financial fields. Since receiving his medical degree from Temple University School of Medicine in 1983, Dr. Rosenwald has been instrumental in the founding and re-capitalization of dozens of public and private biotechnology and life-sciences companies. Dr. Rosenwald believes these companies are revolutionizing the growth and development of new medicines for the 21st century. Paramount’s portfolio companies have seen several new chemical entities approved by the FDA and currently have dozens of compounds in clinical trials. One such company, PolaRx BioPharmaceuticals, Inc., a portfolio company, received final marketing approval for its cancer drug, Arsenic Trioxide, only 30 months after the first patient was treated in a corporate clinical trial, a record in the industry. Dr. Rosenwald believes that the biotechnology industry will see exponential growth over the next 20 years as the demand for safer and more effective treatments are met with significant medical breakthroughs, leading to the effective treatment of human diseases such as cancer and heart disease. Dr. Rosenwald believes that these revolutionary technologies will be developed not by large pharmaceutical companies, but rather by the smaller biotechnology and life-sciences companies that are each dedicated to the development of a few select products. Dr. Rosenwald has launched many successful careers on Wall Street for M.D’s, Ph.D.’s, MBA’s, attorneys and undergraduates and continues to support the medical community through contributions given by his foundation. Dr. Rosenwald currently serves as a director of Cougar Biotechnology, Inc., a publicly traded biotechnology company. Dr. Rosenwald holds a Doctorate of Medicine from Temple University School of Medicine and a B.S. in Finance from Pennsylvania State University.

Lindsay Rosenwald
Chairman / Chief Executive
Paramount Biosciences

If you are interested in learning more about TIGER 21, please complete the contact form and you will receive a copy of our most recent Asset Allocation Report.